BMS enters two separate agreement with Biogen and Roche
BMS (Bristol-Myers Squibb) announced that it has entered into two separate agreements with Biogen and Roche to license to compounds.
BMS-986168, an anti-eTau compound in development…
Read More...
Read More...
